Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.
Identifieur interne : 000419 ( PubMed/Checkpoint ); précédent : 000418; suivant : 000420Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.
Auteurs : R B Belshe [Royaume-Uni] ; M H Smith ; C B Hall ; R. Betts ; A J HaySource :
- Journal of virology [ 0022-538X ] ; 1988.
Descripteurs français
- KwdFr :
- Adamantane (analogues et dérivés), Données de séquences moléculaires, Essais cliniques comme sujet, Grippe humaine (traitement médicamenteux), Humains, Rimantadine (usage thérapeutique), Résistance microbienne aux médicaments (génétique), Séquence d'acides aminés, Séquence nucléotidique, Virus de la grippe A (), Virus de la grippe A (génétique).
- MESH :
- analogues et dérivés : Adamantane.
- génétique : Résistance microbienne aux médicaments, Virus de la grippe A.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Rimantadine.
- Données de séquences moléculaires, Essais cliniques comme sujet, Humains, Séquence d'acides aminés, Séquence nucléotidique, Virus de la grippe A.
English descriptors
- KwdEn :
- MESH :
- chemical , analogs & derivatives : Adamantane.
- drug effects : Influenza A virus.
- drug therapy : Influenza, Human.
- genetics : Drug Resistance, Microbial, Influenza A virus.
- chemical , therapeutic use : Rimantadine.
- Amino Acid Sequence, Base Sequence, Clinical Trials as Topic, Humans, Molecular Sequence Data.
Abstract
The emergence of influenza A viruses which had acquired resistance to rimantadine during a clinical trial (C. B. Hall, R. Dolin, C. L. Gala, D. M. Markovitz, Y. Q. Zhang, P. H. Madore, F. A. Disney, W. B. Talpey, J. L. Green, A. B. Francis, and M. E. Pichichero, Pediatrics 80:275-282, 1987) provided the opportunity to determine the genetic basis of this phenomenon. Analysis of reassortant viruses generated with a resistant clinical isolate (H3N2) and the susceptible influenza A/Singapore/57 (H2N2) virus indicated that RNA segment 7 coding for matrix and M2 proteins conferred the resistant phenotype. Resistant viruses isolated from seven patients each contained a single change in the nucleotide sequence coding for the M2 protein which resulted in substitutions in amino acid 30 (two viruses) or 31 (five viruses) in the transmembrane domain of the molecule. These changes occurred in locations identified in influenza viruses selected for resistance to amantadine in tissue culture and indicate a common mechanism of action of the two compounds in cell culture and during chemotherapeutic use.
PubMed: 3282079
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:3282079Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.</title>
<author><name sortKey="Belshe, R B" sort="Belshe, R B" uniqKey="Belshe R" first="R B" last="Belshe">R B Belshe</name>
<affiliation wicri:level="3"><nlm:affiliation>National Institute for Medical Research, The Ridgeway, Mill Hill, London, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>National Institute for Medical Research, The Ridgeway, Mill Hill, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, M H" sort="Smith, M H" uniqKey="Smith M" first="M H" last="Smith">M H Smith</name>
</author>
<author><name sortKey="Hall, C B" sort="Hall, C B" uniqKey="Hall C" first="C B" last="Hall">C B Hall</name>
</author>
<author><name sortKey="Betts, R" sort="Betts, R" uniqKey="Betts R" first="R" last="Betts">R. Betts</name>
</author>
<author><name sortKey="Hay, A J" sort="Hay, A J" uniqKey="Hay A" first="A J" last="Hay">A J Hay</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1988">1988</date>
<idno type="RBID">pubmed:3282079</idno>
<idno type="pmid">3282079</idno>
<idno type="wicri:Area/PubMed/Corpus">000475</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000475</idno>
<idno type="wicri:Area/PubMed/Curation">000475</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000475</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000419</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000419</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.</title>
<author><name sortKey="Belshe, R B" sort="Belshe, R B" uniqKey="Belshe R" first="R B" last="Belshe">R B Belshe</name>
<affiliation wicri:level="3"><nlm:affiliation>National Institute for Medical Research, The Ridgeway, Mill Hill, London, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>National Institute for Medical Research, The Ridgeway, Mill Hill, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smith, M H" sort="Smith, M H" uniqKey="Smith M" first="M H" last="Smith">M H Smith</name>
</author>
<author><name sortKey="Hall, C B" sort="Hall, C B" uniqKey="Hall C" first="C B" last="Hall">C B Hall</name>
</author>
<author><name sortKey="Betts, R" sort="Betts, R" uniqKey="Betts R" first="R" last="Betts">R. Betts</name>
</author>
<author><name sortKey="Hay, A J" sort="Hay, A J" uniqKey="Hay A" first="A J" last="Hay">A J Hay</name>
</author>
</analytic>
<series><title level="j">Journal of virology</title>
<idno type="ISSN">0022-538X</idno>
<imprint><date when="1988" type="published">1988</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adamantane (analogs & derivatives)</term>
<term>Amino Acid Sequence</term>
<term>Base Sequence</term>
<term>Clinical Trials as Topic</term>
<term>Drug Resistance, Microbial (genetics)</term>
<term>Humans</term>
<term>Influenza A virus (drug effects)</term>
<term>Influenza A virus (genetics)</term>
<term>Influenza, Human (drug therapy)</term>
<term>Molecular Sequence Data</term>
<term>Rimantadine (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adamantane (analogues et dérivés)</term>
<term>Données de séquences moléculaires</term>
<term>Essais cliniques comme sujet</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Humains</term>
<term>Rimantadine (usage thérapeutique)</term>
<term>Résistance microbienne aux médicaments (génétique)</term>
<term>Séquence d'acides aminés</term>
<term>Séquence nucléotidique</term>
<term>Virus de la grippe A ()</term>
<term>Virus de la grippe A (génétique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adamantane</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Adamantane</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A virus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Drug Resistance, Microbial</term>
<term>Influenza A virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Résistance microbienne aux médicaments</term>
<term>Virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Rimantadine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Rimantadine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Base Sequence</term>
<term>Clinical Trials as Topic</term>
<term>Humans</term>
<term>Molecular Sequence Data</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Données de séquences moléculaires</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Séquence d'acides aminés</term>
<term>Séquence nucléotidique</term>
<term>Virus de la grippe A</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The emergence of influenza A viruses which had acquired resistance to rimantadine during a clinical trial (C. B. Hall, R. Dolin, C. L. Gala, D. M. Markovitz, Y. Q. Zhang, P. H. Madore, F. A. Disney, W. B. Talpey, J. L. Green, A. B. Francis, and M. E. Pichichero, Pediatrics 80:275-282, 1987) provided the opportunity to determine the genetic basis of this phenomenon. Analysis of reassortant viruses generated with a resistant clinical isolate (H3N2) and the susceptible influenza A/Singapore/57 (H2N2) virus indicated that RNA segment 7 coding for matrix and M2 proteins conferred the resistant phenotype. Resistant viruses isolated from seven patients each contained a single change in the nucleotide sequence coding for the M2 protein which resulted in substitutions in amino acid 30 (two viruses) or 31 (five viruses) in the transmembrane domain of the molecule. These changes occurred in locations identified in influenza viruses selected for resistance to amantadine in tissue culture and indicate a common mechanism of action of the two compounds in cell culture and during chemotherapeutic use.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3282079</PMID>
<DateCompleted><Year>1988</Year>
<Month>05</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-538X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>62</Volume>
<Issue>5</Issue>
<PubDate><Year>1988</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.</ArticleTitle>
<Pagination><MedlinePgn>1508-12</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The emergence of influenza A viruses which had acquired resistance to rimantadine during a clinical trial (C. B. Hall, R. Dolin, C. L. Gala, D. M. Markovitz, Y. Q. Zhang, P. H. Madore, F. A. Disney, W. B. Talpey, J. L. Green, A. B. Francis, and M. E. Pichichero, Pediatrics 80:275-282, 1987) provided the opportunity to determine the genetic basis of this phenomenon. Analysis of reassortant viruses generated with a resistant clinical isolate (H3N2) and the susceptible influenza A/Singapore/57 (H2N2) virus indicated that RNA segment 7 coding for matrix and M2 proteins conferred the resistant phenotype. Resistant viruses isolated from seven patients each contained a single change in the nucleotide sequence coding for the M2 protein which resulted in substitutions in amino acid 30 (two viruses) or 31 (five viruses) in the transmembrane domain of the molecule. These changes occurred in locations identified in influenza viruses selected for resistance to amantadine in tissue culture and indicate a common mechanism of action of the two compounds in cell culture and during chemotherapeutic use.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Belshe</LastName>
<ForeName>R B</ForeName>
<Initials>RB</Initials>
<AffiliationInfo><Affiliation>National Institute for Medical Research, The Ridgeway, Mill Hill, London, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Smith</LastName>
<ForeName>M H</ForeName>
<Initials>MH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hall</LastName>
<ForeName>C B</ForeName>
<Initials>CB</Initials>
</Author>
<Author ValidYN="Y"><LastName>Betts</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hay</LastName>
<ForeName>A J</ForeName>
<Initials>AJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName>
<AccessionNumberList><AccessionNumber>M20326</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y"><Grant><GrantID>N01-A1-52575</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0T2EF4JQTU</RegistryNumber>
<NameOfSubstance UI="D012299">Rimantadine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>PJY633525U</RegistryNumber>
<NameOfSubstance UI="D000218">Adamantane</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000218" MajorTopicYN="N">Adamantane</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004352" MajorTopicYN="N">Drug Resistance, Microbial</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012299" MajorTopicYN="N">Rimantadine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year>
<Month>5</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1988</Year>
<Month>5</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1988</Year>
<Month>5</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">3282079</ArticleId>
<ArticleId IdType="pmc">PMC253174</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>EMBO J. 1985 Nov;4(11):3021-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4065098</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1985 Jul;55(1):173-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4009792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 1986 Oct;18 Suppl B:135-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3793655</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 1986 Oct;18 Suppl B:19-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3793659</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 1987 Mar;21(3):249-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3549971</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 1987 Aug;80(2):275-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3302925</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1964 May 15;144(3620):862-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14151624</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med Sci. 1969 May;257(5):328-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4891873</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1969 Sep 11;281(11):579-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4897137</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1970 Apr 4;226(5240):82-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5434369</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1977 Aug;36(2):249-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">561163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">271968</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1979 Jan;42(1):189-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">759556</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1978 Dec;28(3):710-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">731792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 1980 May;17(5):865-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7396473</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 1981 Mar 20;245(11):1128-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7007668</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1981 Jul 30;112(2):746-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7257189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Infect Dis. 1981 May-Jun;3(3):408-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7025146</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1981 Jul;78(7):4170-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6945577</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1982 Sep 2;307(10):580-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7050702</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gene. 1983 Aug;23(2):233-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6688599</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 1985 Mar;40(3):627-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3882238</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 1986 Feb;29(2):339-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3521480</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Betts, R" sort="Betts, R" uniqKey="Betts R" first="R" last="Betts">R. Betts</name>
<name sortKey="Hall, C B" sort="Hall, C B" uniqKey="Hall C" first="C B" last="Hall">C B Hall</name>
<name sortKey="Hay, A J" sort="Hay, A J" uniqKey="Hay A" first="A J" last="Hay">A J Hay</name>
<name sortKey="Smith, M H" sort="Smith, M H" uniqKey="Smith M" first="M H" last="Smith">M H Smith</name>
</noCountry>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Belshe, R B" sort="Belshe, R B" uniqKey="Belshe R" first="R B" last="Belshe">R B Belshe</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000419 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000419 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:3282079 |texte= Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:3282079" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |